Literature DB >> 27047955

Mutations at the splice sites of exon 14 of MET gene: a new target for sarcomatoid carcinomas?

Marie Wislez1, Charlotte Domblides1, Alexis Cortot1, Antoinette Lemoine1.   

Abstract

Entities:  

Year:  2016        PMID： 27047955      PMCID： PMC4791342          DOI： 10.21037/atm.2016.01.12

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  11 in total

1.  Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.

Authors:  Garrett M Frampton; Siraj M Ali; Mark Rosenzweig; Juliann Chmielecki; Xinyuan Lu; Todd M Bauer; Mikhail Akimov; Jose A Bufill; Carrie Lee; David Jentz; Rick Hoover; Sai-Hong Ignatius Ou; Ravi Salgia; Tim Brennan; Zachary R Chalmers; Savina Jaeger; Alan Huang; Julia A Elvin; Rachel Erlich; Alex Fichtenholtz; Kyle A Gowen; Joel Greenbowe; Adrienne Johnson; Depinder Khaira; Caitlin McMahon; Eric M Sanford; Steven Roels; Jared White; Joel Greshock; Robert Schlegel; Doron Lipson; Roman Yelensky; Deborah Morosini; Jeffrey S Ross; Eric Collisson; Malte Peters; Philip J Stephens; Vincent A Miller
Journal:  Cancer Discov       Date:  2015-05-13       Impact factor: 39.397

2.  Efficacy of first-line chemotherapy in patients with advanced lung sarcomatoid carcinoma.

Authors:  Thibault Vieira; Nicolas Girard; Mony Ung; Isabelle Monnet; Aurélie Cazes; Pierre Bonnette; Michael Duruisseaux; Julien Mazieres; Martine Antoine; Jacques Cadranel; Marie Wislez
Journal:  J Thorac Oncol       Date:  2013-12       Impact factor: 15.609

3.  c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.

Authors:  Patrick C Ma; Takashi Kijima; Gautam Maulik; Edward A Fox; Martin Sattler; James D Griffin; Bruce E Johnson; Ravi Salgia
Journal:  Cancer Res       Date:  2003-10-01       Impact factor: 12.701

4.  Clinical and molecular features in patients with advanced non-small-cell lung carcinoma refractory to first-line platinum-based chemotherapy.

Authors:  E Giroux Leprieur; M Antoine; T Vieira; M Duruisseaux; V Poulot; N Rabbe; L Belmont; V Gounant; A Lavolé; B Milleron; R Lacave; J Cadranel; M Wislez
Journal:  Lung Cancer       Date:  2012-11-13       Impact factor: 5.705

5.  Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers.

Authors:  Ryoichi Onozato; Takayuki Kosaka; Hiroyuki Kuwano; Yoshitaka Sekido; Yasushi Yatabe; Tetsuya Mitsudomi
Journal:  J Thorac Oncol       Date:  2009-01       Impact factor: 15.609

6.  Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations.

Authors:  Xuewen Liu; Yuxia Jia; Mark B Stoopler; Yufeng Shen; Haiying Cheng; Jinli Chen; Mahesh Mansukhani; Sanjay Koul; Balazs Halmos; Alain C Borczuk
Journal:  J Clin Oncol       Date:  2015-07-27       Impact factor: 44.544

7.  Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer.

Authors:  Katsuhiro Okuda; Hidefumi Sasaki; Haruhiro Yukiue; Motoki Yano; Yoshitaka Fujii
Journal:  Cancer Sci       Date:  2008-11       Impact factor: 6.716

8.  The transcriptional landscape and mutational profile of lung adenocarcinoma.

Authors:  Jeong-Sun Seo; Young Seok Ju; Won-Chul Lee; Jong-Yeon Shin; June Koo Lee; Thomas Bleazard; Junho Lee; Yoo Jin Jung; Jung-Oh Kim; Jung-Young Shin; Saet-Byeol Yu; Jihye Kim; Eung-Ryoung Lee; Chang-Hyun Kang; In-Kyu Park; Hwanseok Rhee; Se-Hoon Lee; Jong-Il Kim; Jin-Hyoung Kang; Young Tae Kim
Journal:  Genome Res       Date:  2012-09-13       Impact factor: 9.043

9.  Transcriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes.

Authors:  Saravana M Dhanasekaran; O Alejandro Balbin; Guoan Chen; Ernest Nadal; Shanker Kalyana-Sundaram; Jincheng Pan; Brendan Veeneman; Xuhong Cao; Rohit Malik; Pankaj Vats; Rui Wang; Stephanie Huang; Jinjie Zhong; Xiaojun Jing; Matthew Iyer; Yi-Mi Wu; Paul W Harms; Jules Lin; Rishindra Reddy; Christine Brennan; Nallasivam Palanisamy; Andrew C Chang; Anna Truini; Mauro Truini; Dan R Robinson; David G Beer; Arul M Chinnaiyan
Journal:  Nat Commun       Date:  2014-12-22       Impact factor: 14.919

10.  Comprehensive molecular profiling of lung adenocarcinoma.

Authors: 
Journal:  Nature       Date:  2014-07-09       Impact factor: 49.962
View more
  3 in total

Review 1.  MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy.

Authors:  Sara Pilotto; Anastasios Gkountakos; Luisa Carbognin; Aldo Scarpa; Giampaolo Tortora; Emilio Bria
Journal:  Ann Transl Med       Date:  2017-01

2.  The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study.

Authors:  George M Burslem; Blake E Smith; Ashton C Lai; Saul Jaime-Figueroa; Daniel C McQuaid; Daniel P Bondeson; Momar Toure; Hanqing Dong; Yimin Qian; Jing Wang; Andrew P Crew; John Hines; Craig M Crews
Journal:  Cell Chem Biol       Date:  2017-11-09       Impact factor: 8.116

3.  Frequency of MET exon 14 skipping mutations in non-small cell lung cancer according to technical approach in routine diagnosis: results from a real-life cohort of 2,369 patients.

Authors:  Anne Champagnac; Pierre-Paul Bringuier; Marc Barritault; Sylvie Isaac; Emmanuel Watkin; Fabien Forest; Jean-Michel Maury; Nicolas Girard; Marie Brevet
Journal:  J Thorac Dis       Date:  2020-05       Impact factor: 2.895
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.